カテゴリ： visiongain, 世界, 医療/バイオ

アルツハイマー病治療のグローバル市場2022-2032：ドネペジル、リバスチグミン、メマンチン

■ 英語タイトル：Alzheimer's Therapeutics Market Report 2022-2032 : Forecasts by Drug (Donepezil, Rivastigmine, Memantine, Galantamine, Manufactured Combination of Memantine and Donepezil), by Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Manufactured Combination), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

調査会社visiongain社が発行したリサーチレポート（データ管理コード：VGA23FB020）■ 発行会社/調査会社：visiongain
■ 商品コード：VGA23FB020
■ 発行日：2022年12月9日
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：196
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Sigle User（1名様閲覧用、1年間、印刷不可）GBP3,950 ⇒換算￥750,500見積依頼/購入/質問フォーム
Enterprise（法人閲覧用、1年間、印刷可）GBP6,950 ⇒換算￥1,320,500見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[アルツハイマー病治療のグローバル市場2022-2032：ドネペジル、リバスチグミン、メマンチン]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Visiongain社の本調査資料は、世界のアルツハイマー病治療市場規模が2032年までにCAGR 9.17%で成長すると推測しています。本資料は、アルツハイマー病治療の世界市場について幅広く調査を行い、レポート概要、エグゼクティブサマリー、市場動向、薬物別（ドネペジル、リバスチグミン、メマンチン）分析、薬物クラス別（コリンエステラーゼ阻害剤、NMDA受容体拮抗薬、製造配合剤）分析、流通チャネル別（病院薬局、小売薬局、ドラッグストア、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、企業情報など、以下のようにまとめています。尚、AbbVie, Inc.、Amneal Pharmaceuticals Inc.、Aurobindo Pharma Ltd、Cipla Ltd.、Dr. Reddy's Laboratories Ltd、Eisai Co., Ltd.、Janssen Pharmaceuticals, Inc. 、Lupin Ltd、Macleods Pharmaceuticals Ltd.、Novartis AG、Sun Pharmaceutical Industries Ltd.などの企業情報を含んでいます。
・レポート概要
・エグゼクティブサマリー
・市場動向
・世界のアルツハイマー病治療市場規模：薬物別
- ドネペジルの市場規模
- リバスチグミンの市場規模
- メマンチンの市場規模
・世界のアルツハイマー病治療市場規模：薬物クラス別
- コリンエステラーゼ阻害剤の市場規模
- NMDA受容体拮抗薬の市場規模
- 製造配合剤の市場規模
・世界のアルツハイマー病治療市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- ドラッグストアチャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界のアルツハイマー病治療市場規模：地域別
- 北米のアルツハイマー病治療市場規模
- ヨーロッパのアルツハイマー病治療市場規模
- アジア太平洋のアルツハイマー病治療市場規模
- 中南米のアルツハイマー病治療市場規模
- 中東・アフリカのアルツハイマー病治療市場規模
・企業情報

The Alzheimer’s Therapeutics Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Large Number of Undiagnosed Patient Pool to Propel Growth
Residents who have been diagnosed with early-stage Alzheimer’s disease and some forms of dementia do not have adequate access to the healthcare system to fully diagnose and treat the condition. For instance, according to the 2021 World Alzheimer Report, only 46% of dementia patients and those who provide care recognised stigma and fear of a diagnosis as diagnostic hurdles. The market for Alzheimer’s medications is anticipated to expand due to the 10% underdiagnosis rate in low- and middle-income countries. The U.S. Food and Drug Administration (FDA) has already given its approval to a number of medication medications to help manage symptoms in Alzheimer’s patients. Aducanumab, a new drug that helps to reduce amyloid deposits in the brain and may slow the progression of Alzheimer’s, received accelerated approval from the FDA on June 7, 2021. However, it has not yet been demonstrated that it has an impact on clinical symptoms or outcomes, such as the progression of cognitive decline or dementia disease. On the other hand, the Alzheimer’s therapeutics business is struggling with a labour shortage that prevents it from meeting the rising demand for Parkinson’s and dementia medications. Over the projected period, it is anticipated that this factor will limit the market for Alzheimer’s therapeutics acceptance worldwide.

Increasing Occurrence of Alzheimer’s to Boost Market Growth
The market for Alzheimer’s disease medicines is anticipated to develop as the prevalence and incidence of the condition rise globally. The incidence of the disease rises due to an increasing senior population worldwide, which also presents a growth opportunity for the Alzheimer’s therapeutics industry. For example, the World Population Prospects (WPP), issued by the United Nations in 2021, estimates that 771 million people worldwide are 65 or older, which is three times the number in 1980. By 2030, the population is expected to increase by 3% annually, reaching 1.4 billion. As a result, these regions are prospective growth areas for the Alzheimer’s therapeutics market.

What Questions Should You Ask before Buying a Market Research Report?
• How is the Alzheimer’s Therapeutics market evolving?
• What is driving and restraining the Alzheimer’s Therapeutics market?
• How will each Alzheimer’s Therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each Alzheimer’s Therapeutics submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading Alzheimer’s Therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Alzheimer’s Therapeutics projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of Alzheimer’s Therapeutics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Alzheimer’s Therapeutics market?
• Where is the Alzheimer’s Therapeutics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Alzheimer’s Therapeutics market today, and over the next 10 years:
• Our 196-page report provides 95 tables, 137 charts exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Alzheimer’s Therapeutics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Alzheimer’s Therapeutics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Drug Type
• Donepezil
• Rivastigmine
• Memantine
• Galantamine
• Manufactured Combination of Memantine and Donepezil

Drug Class
• Cholinesterase Inhibitors
• NMDA Receptor Antagonists
• Manufactured Combination

Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 17 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Alzheimer’s Therapeutics Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• AbbVie, Inc.
• Amneal Pharmaceuticals Inc.
• Aurobindo Pharma Ltd
• Cipla Ltd.
• Dr. Reddy’s Laboratories Ltd
• Eisai Co., Ltd.
• Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
• Lupin Ltd
• Macleods Pharmaceuticals Ltd.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Ltd., Inc.
• Torrent pharmaceuticals ltd.
• Viatris Inc.
• Zydus Lifesciences Ltd

Overall world revenue for Alzheimer’s Therapeutics Market, 2022 to 2032 in terms of value the market will surpass US$2,870 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Alzheimer’s Therapeutics Market, 2022 to 2032 report help you?
In summary, our 190+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Alzheimer’s Therapeutics Market, 2022 to 2032 Market, with forecasts for drug type, drug class, and distribution channel, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for five regional and 17 key national markets – See forecasts for the Alzheimer’s Therapeutics Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, South Korea, Australia and South Africa among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 15 of the major companies involved in the Alzheimer’s Therapeutics Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Alzheimer’s Therapeutics Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Alzheimer’s Therapeutics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Occurrence of Alzheimer’s Disease to Drive Market Growth
3.2.1.2 Large Number of Undiagnosed Patient’s and Revised Diagnostic Guidelines to Propel Growth
3.2.2 Market Restraining Factors
3.2.2.1 Shortage of Skilled Medical Professionals
3.2.2.2 Lack of Proper Treatment Techniques
3.2.3 Market Opportunities
3.2.3.1 Surge in Number of Mergers and Acquisitions to Boost Market Growth
3.2.3.2 Increasing R&D Investments and Collaborations
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PESTLE Analysis

4 Alzheimer’s Therapeutics Market Analysis by Drug
4.1 Key Findings
4.2 Drug Segment: Market Attractiveness Index
4.3 Alzheimer’s Therapeutics Market Share by Drug, 2022 & 2032
4.4 Donepezil
4.4.1 Donepezil Market Forecast by Region, 2022-2032 (US$ Mn)
4.4.2 Donepezil Market Share by Region, 2022 & 2032 (%)
4.5 Rivastigmine
4.5.1 Rivastigmine Market Forecast by Region, 2022-2032 (US$ Mn)
4.5.2 Rivastigmine Market Share by Region, 2022 & 2032 (%)
4.6 Memantine
4.6.1 Memantine Market Share by Region, 2022 & 2032 (%)
4.6.2 Memantine Market Share by Region, 2022 & 2032 (%)
4.7 Galantamine
4.7.1 Galantamine Market Forecast by Region, 2022-2032 (US$ Mn)
4.7.2 Galantamine Market Share by Region, 2022 & 2032 (%)
4.8 Manufactured Combination of Memantine and Donepezil
4.8.1 Manufactured Combination of Memantine and Donepezil Market Forecast by Region, 2022-2032 (US$ Mn)
4.8.2 Manufactured Combination of Memantine and Donepezil Market Share by Region, 2022 & 2032 (%)

5 Alzheimer’s Therapeutics Market Analysis by Drug Class
5.1 Key Findings
5.2 Drug Class Segment: Market Attractiveness Index
5.3 Alzheimer’s Therapeutics Market Share by Drug Class, 2022 & 2032
5.4 Cholinesterase Inhibitors
5.4.1 Cholinesterase Inhibitors Market Forecast by Region, 2022-2032 (US$ Mn)
5.4.2 Cholinesterase Inhibitors Market Share by Region, 2022 & 2032 (%)
5.5 NMDA Receptor Antagonists
5.5.1 NMDA Receptor Antagonists Market Forecast by Region, 2022-2032 (US$ Mn)
5.5.2 NMDA Receptor Antagonists Market Share by Region, 2022 & 2032 (%)
5.6 Manufactured Combination
5.6.1 Manufactured Combination Market Forecast by Region, 2022-2032 (US$ Mn)
5.6.2 Manufactured Combination Market Share by Region, 2022 & 2032 (%)

6 Alzheimer’s Therapeutics Market Analysis by Distribution Channel
6.1 Key Findings
6.2 Distribution Channel Segment: Market Attractiveness Index
6.3 Alzheimer’s Therapeutics Market Share by Distribution Channel, 2022 & 2032
6.4 Hospital Pharmacies
6.4.1 Hospital Pharmacies Market Forecast by Region, 2022-2032 (US$ Mn)
6.4.2 Hospital Pharmacies Market Share by Region, 2022 & 2032 (%)
6.5 Retail Pharmacies
6.5.1 Retail Pharmacies Market Forecast by Region, 2022-2032 (US$ Mn)
6.5.2 Retail Pharmacies Market Share by Region, 2022 & 2032 (%)
6.6 Drug Stores
6.6.1 Drug Stores Market Forecast by Region, 2022-2032 (US$ Mn)
6.6.2 Drug Stores Market Share by Region, 2022 & 2032 (%)
6.7 Online Pharmacies
6.7.1 Online Pharmacies Market Forecast by Region, 2022-2032 (US$ Mn)
6.7.2 Online Pharmacies by Region, 2022 & 2032 (%)

7 Alzheimer’s Therapeutics Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast

8 North America Alzheimer’s Therapeutics Market Analysis
8.1 Key Findings
8.2 North America Alzheimer’s Therapeutics Market by Country, 2022, 2027 & 2032 (US$ mn)
8.3 North America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
8.4 North America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug
8.5 North America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
8.6 North America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
8.7 U.S. Alzheimer’s Therapeutics Market Analysis
8.8 Canada Alzheimer’s Therapeutics Market Analysis

9 Europe Alzheimer’s Therapeutics Market Analysis
9.1 Key Findings
9.2 Europe Alzheimer’s Therapeutics Market by Country, 2022, 2027 & 2032 (US$ mn)
9.3 Europe Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
9.4 Europe Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug
9.5 Europe Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
9.6 Europe Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
9.7 Germany Alzheimer’s Therapeutics Market Analysis
9.8 UK Alzheimer’s Therapeutics Market Analysis
9.9 France Alzheimer’s Therapeutics Market Analysis
9.10 Italy Alzheimer’s Therapeutics Market Analysis
9.11 Spain Alzheimer’s Therapeutics Market Analysis
9.12 Russia Alzheimer’s Therapeutics Market Analysis
9.13 Rest of Europe Alzheimer’s Therapeutics Market Analysis

10 Asia-Pacific Alzheimer’s Therapeutics Market Analysis
10.1 Key Findings
10.2 Asia-Pacific Alzheimer’s Therapeutics Market by Country, 2022, 2027 & 2032 (US$ mn)
10.3 Asia-Pacific Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
10.4 Asia-Pacific Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug
10.5 Asia-Pacific Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
10.6 Asia-Pacific Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
10.7 Japan Alzheimer’s Therapeutics Market Analysis
10.8 China Alzheimer’s Therapeutics Market Analysis
10.9 India Alzheimer’s Therapeutics Market Analysis
10.10 Australia Alzheimer’s Therapeutics Market Analysis
10.11 South Korea Alzheimer’s Therapeutics Market Analysis
10.12 Rest of Asia Pacific Alzheimer’s Therapeutics Market Analysis

11 Latin America Alzheimer’s Therapeutics Market Analysis
11.1 Key Findings
11.2 Latin America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
11.3 Latin America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug
11.4 Latin America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
11.5 Latin America Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
11.6 Brazil Alzheimer’s Therapeutics Market Analysis
11.7 Mexico Alzheimer’s Therapeutics Market Analysis
11.8 Rest of Latin America Alzheimer’s Therapeutics Market Analysis

12 MEA Alzheimer’s Therapeutics Market Analysis
12.1 Key Findings
12.2 MEA Alzheimer’s Therapeutics Market by Country, 2022, 2027 & 2032 (US$ mn)
12.3 MEA Alzheimer’s Therapeutics Market Size Estimation and Forecast by Country
12.4 MEA Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug
12.5 MEA Alzheimer’s Therapeutics Market Size Estimation and Forecast by Drug Class
12.6 MEA Alzheimer’s Therapeutics Market Size Estimation and Forecast by Distribution Channel
12.7 GCC Alzheimer’s Therapeutics Market Analysis
12.8 South Africa Alzheimer’s Therapeutics Market Analysis
12.9 Rest of MEA Alzheimer’s Therapeutics Market Analysis

13 Company Profiles
13.1 Company Share Analysis
13.2 AbbVie, Inc.
13.2.1 Company Snapshot
13.2.2 Company Overview
13.2.3 Financial Analysis
13.2.3.1 Net Revenue, 2017-2021
13.2.3.2 Regional Market Shares, 2021
13.2.3.3 Business Segment Market Shares, 2021
13.2.4 Product Benchmarking
13.2.5 Strategic Outlook
13.3 Teva Pharmaceuticals Ltd., Inc.
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.3.1 Net Revenue, 2017-2021
13.3.3.2 Regional Market Shares, 2021
13.3.4 Product Benchmarking
13.3.5 Strategic Outlook
13.4 Eisai Co., Ltd.
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Analysis
13.4.3.1 Net Revenue, 2017-2021
13.4.3.2 Regional Market Shares, 2020
13.4.4 Product Benchmarking
13.4.5 Strategic Outlook
13.5 Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis
13.5.3.1 Net Revenue, 2017-2021
13.5.4 Product Benchmarking
13.6 Novartis AG
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Analysis
13.6.3.1 Net Revenue, 2017-2021
13.6.4 Product Benchmarking
13.6.5 Strategic Outlook
13.7 Zydus Lifesciences Ltd (CADILA)
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.3.1 Net Revenue, 2017-2021
13.7.3.2 Business Market Shares, 2021
13.7.4 Product Benchmarking
13.8 Sun Pharmaceutical Industries Ltd.
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Financial Analysis
13.8.3.1 Net Revenue, 2017-2021
13.8.4 Product Benchmarking
13.9 Dr. Reddy’s Laboratories Ltd
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis
13.9.3.1 Net Revenue, 2017-2021
13.9.3.2 Regional Market Shares, 2021
13.9.3.3 Business Market Shares, 2021
13.9.4 Product Benchmarking
13.10 Aurobindo Pharma Ltd
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Financial Analysis
13.10.3.1 Net Revenue, 2017-2021
13.10.3.2 Business Market Shares, 2021
13.10.4 Product Benchmarking
13.11 Amneal Pharmaceuticals Inc.
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis
13.11.3.1 Net Revenue, 2017-2021
13.11.3.2 Business Market Shares, 2021
13.11.4 Product Benchmarking
13.11.5 Strategic Outlook
13.12 Macleods Pharmaceuticals Ltd.
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Financial Analysis
13.12.3.1 Net Revenue, 2018-2020
13.12.3.2 Regional Market Shares, 2020
13.12.3.3 Business Market Shares, 2020
13.12.4 Product Benchmarking
13.13 Viatris Inc.
13.13.1 Company Snapshot
13.13.2 Company Overview
13.13.3 Financial Analysis
13.13.3.1 Net Revenue, 2017-2021
13.13.4 Product Benchmarking
13.14 Lupin Ltd
13.14.1 Company Snapshot
13.14.2 Company Overview
13.14.3 Financial Analysis
13.14.3.1 Net Revenue, 2017-2021
13.14.3.2 Regional Market Shares, 2021
13.14.3.3 Business Market Shares, 2021
13.14.4 Product Benchmarking
13.15 Cipla Ltd.
13.15.1 Company Snapshot
13.15.2 Company Overview
13.15.3 Financial Analysis
13.15.3.1 Net Revenue, 2017-2021
13.15.3.2 Business Market Shares, 2021
13.15.4 Product Benchmarking
13.15.5 Strategic Outlook
13.16 Torrent pharmaceuticals ltd.
13.16.1 Company Snapshot
13.16.2 Company Overview
13.16.3 Financial Analysis
13.16.3.1 Net Revenue, 2017-2021
13.16.4 Product Benchmarking

14 Conclusion and Recommendations
14.1 Concluding Remarks from
14.2 Recommendations for Market Players



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • アルツハイマー病治療薬のグローバル市場展望 2023年-2029年：ドネペジル、メマンチン、リバスチグミン、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(VGA23FB020 )"アルツハイマー病治療のグローバル市場2022-2032：ドネペジル、リバスチグミン、メマンチン" (英文：Alzheimer's Therapeutics Market Report 2022-2032 : Forecasts by Drug (Donepezil, Rivastigmine, Memantine, Galantamine, Manufactured Combination of Memantine and Donepezil), by Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Manufactured Combination), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis)はvisiongain社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。